Table 3. X ± s, above/below the normal rang of SF, Hb, TRF in female primary lung cancer patients.
| Parameters | Serum ferritin | Hemoglobin | Transferrin | ||||||
|---|---|---|---|---|---|---|---|---|---|
| x ± s (ug/l) | above (n) | above (%) | x ± s (g/l) | below (n) | below(%) | x ±s (g/l) | below (n) | below (%) | |
| Menopause | P=0.000 | P=0.112 | P=0.008 | ||||||
| Yes | 259.7±132.1 | 144 | 80.0 | 123.9±14.6 | 24 | 13.3 | 2.3±0.5 | 72 | 40.0 |
| No | 121.8±123.3 | 19 | 26.4 | 120.7±14.1 | 12 | 16.7 | 2.6±0.7 | 22 | 30.6 |
| Pathologic type* | P=0.645 | P=0.424 | P=0.149 | ||||||
| Adenocarcinoma | 224.7±143.9 | 132 | 67.0 | 123.5±14.8 | 27 | 13.7 | 2.5±0.6 | 69 | 35.0 |
| Squamous cell carcinoma | 197.9±146.6 | 15 | 60.0 | 121.8±13.0 | 4 | 16.0 | 2.2±0.6 | 11 | 44.0 |
| Adeno-squamous carcinoma | 184.0±155.8 | 3 | 37.5 | 122.0±9.4 | 1 | 12.5 | 2.2±0.7 | 5 | 62.5 |
| Small cell carcinoma | 174.6±113.9 | 3 | 37.5 | 113.5±16.3 | 3 | 37.5 | 2.3±0.4 | 3 | 37.5 |
| Not classifiable/others | 244.6±149.8 | 10 | 71.4 | 123.5±14.5 | 1 | 7.1 | 2.2±0.5 | 6 | 42.9 |
| Stage* | P=0.546 | P=0.344 | P=0.348 | ||||||
| I | 198.7±136.4 | 39 | 60.9 | 125.1±12.8 | 8 | 12.5 | 2.5±0.6 | 19 | 29.7 |
| II | 216.5±120.2 | 12 | 70.6 | 118.2±17.5 | 4 | 23.5 | 2.3±0.4 | 6 | 35.3 |
| III | 244.0±156.3 | 43 | 71.7 | 124.0±13.0 | 8 | 13.3 | 2.3±0.5 | 24 | 40.0 |
| IV | 220.2±139.5 | 60 | 61.9 | 122.3±14.9 | 12 | 12.4 | 2.4±0.6 | 37 | 38.1 |
| Not classifiable | 222.1±176.5 | 9 | 64.3 | 119.4±20.1 | 4 | 28.6 | 2.3±0.6 | 8 | 57.1 |
| T* | P=0.153 | P=0.086 | P=0.058 | ||||||
| T1 | 192.3±119.5 | 42 | 67.7 | 126.6±13.0 | 8 | 12.9 | 2.6±0.5 | 14 | 22.6 |
| T2 | 225.9±148.5 | 65 | 61.3 | 123.0±12.8 | 11 | 10.4 | 2.4±0.6 | 37 | 34.9 |
| T3 | 266.4±158.6 | 28 | 75.7 | 118.9±17.4 | 8 | 21.6 | 2.3±0.6 | 18 | 48.6 |
| T4 | 205.4±135.9 | 14 | 56.0 | 119.7±16.3 | 5 | 20.0 | 2.3±0.7 | 14 | 56.0 |
| Tx (Not classifiable) | 211.2±155.5 | 14 | 63.6 | 123.4±17.6 | 4 | 18.2 | 2.4±0.7 | 11 | 50.0 |
| N* | P=0.101 | P=0.787 | P=0.038 | ||||||
| N0 | 197.0±135.7 | 45 | 59.2 | 124.2±14.2 | 10 | 13.2 | 2.5±0.6 | 22 | 28.9 |
| N1 | 186.9±111.3 | 12 | 57.1 | 123.6±9.8 | 1 | 4.8 | 2.6±0.7 | 6 | 28.6 |
| N2 | 228.1±140.3 | 60 | 68.2 | 122.8±15.6 | 14 | 15.9 | 2.3±0.5 | 35 | 39.8 |
| N3 | 264.3±163.2 | 32 | 71.1 | 120.7±13.3 | 7 | 15.6 | 2.2±0.6 | 20 | 44.4 |
| Nx (Not classifiable) | 211.2±155.5 | 14 | 63.6 | 123.4±17.6 | 4 | 18.2 | 2.4±0.7 | 11 | 50.0 |
| M* | P=0.999 | P=0.488 | P=0.661 | ||||||
| M0 | 220.1±144.1 | 94 | 66.7 | 123.8±13.6 | 20 | 14.2 | 2.4±0.6 | 49 | 34.8 |
| M1 | 220.2±139.5 | 60 | 61.9 | 122.3±14.9 | 12 | 12.4 | 2.4±0.6 | 37 | 38.1 |
| Mx (Not classifiable) | 222.1±176.5 | 9 | 64.3 | 119.4±20.1 | 4 | 28.6 | 2.3±0.6 | 8 | 57.1 |
* P>0.05. χ2 test in the composition of postmenopausal patients and premenopausal patients.